Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
249.59
+2.46 (1.00%)
At close: Nov 20, 2026, 4:00 PM EST
250.00
+0.41 (0.16%)
After-hours: Nov 20, 2026, 7:55 PM EST
Biogen Market Cap
Biogen has a market cap or net worth of $36.89 billion as of November 20, 2026. It is the 640th most valuable company in the world and the 296th biggest in the United States. Its market cap has increased by 49.76% in one year.
Market Cap
36.89B
Enterprise Value
43.39B
1-Year Change
49.76%
Global Rank
Country Rank
#296 United States
Category
ChartMarket Cap Chart
Since December 1, 1998, Biogen's market cap has increased from $617.50M to $36.89B, an increase of 5,874.81%. That is a compound annual growth rate of 15.74%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 20, 2026 | 36.89B | 42.90% |
| Dec 31, 2025 | 25.82B | 15.86% |
| Dec 31, 2024 | 22.28B | -40.57% |
| Dec 29, 2023 | 37.50B | -5.97% |
| Dec 30, 2022 | 39.88B | 13.15% |
| Dec 31, 2021 | 35.24B | -6.47% |
| Dec 31, 2020 | 37.68B | -29.63% |
| Dec 31, 2019 | 53.54B | -11.69% |
| Dec 31, 2018 | 60.63B | -10.00% |
| Dec 29, 2017 | 67.37B | 9.19% |
| Dec 30, 2016 | 61.70B | -9.65% |
| Dec 31, 2015 | 68.29B | -14.82% |
| Dec 31, 2014 | 80.16B | 21.39% |
| Dec 31, 2013 | 66.04B | 90.69% |
| Dec 31, 2012 | 34.63B | 29.54% |
| Dec 30, 2011 | 26.73B | 67.31% |
| Dec 31, 2010 | 15.98B | 3.27% |
| Dec 31, 2009 | 15.47B | 11.34% |
| Dec 31, 2008 | 13.90B | -16.78% |
| Dec 31, 2007 | 16.70B | 0.70% |
| Dec 29, 2006 | 16.58B | 7.90% |
| Dec 30, 2005 | 15.37B | -30.83% |
| Dec 31, 2004 | 22.22B | 288.89% |
| Dec 31, 2003 | 5.71B | 12.55% |
| Dec 31, 2002 | 5.08B | -51.71% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Merck & Co. | 329.65B |
| Novartis AG | 287.51B |
| AstraZeneca | 272.50B |
| Amgen | 235.64B |
| Gilead Sciences | 206.43B |
| Novo Nordisk | 171.34B |
| Pfizer | 156.18B |
| Bristol-Myers Squibb Company | 120.19B |